Gilead settles patent case around HIV drug Descovy - San Francisco Business Times

HIV drug pioneer Gilead Sciences Inc. made sure its leadership spot is well protected into 2032, settling a case this week with the makers of five potential generic versions of its second-generation HIV prevention drug Descovy.

, which would be groundbreaking because it would be injected just under the skin only twice a year to treat HIV. Gilead also is studying lenacapavir as a possible long-term PrEP medication. The HIV prevention market, which tailed off like other drug markets during the height of Covid-19 pandemic lockdowns, grew in the first couple quarters of this year, O'Day said.

It wasn't clear what else the companies may have received in return for agreeing in U.S. District Court in Delaware to delay commercialization of their lower-cost generics.

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Berkeley pizza joint adds new location in Stonestown Galleria - San Francisco Business TimesThis would make two S.F. mall stops for the longtime pizza fixture on Telegraph Avenue.
Source: SFBusinessTimes - 🏆 78. / 68 Read more »

Vir Biotechnology opens new office in St. Louis - San Francisco Business TimesThe San Francisco-based immunology company that wants to help eradicate infectious disease globally has expanded its footprint in St. Louis, opening a new $41 million office within the Cortex innovation district. It says the new facility will be critical to advancing research to treat several infectious diseases, including Covid-19.
Source: SFBusinessTimes - 🏆 78. / 68 Read more »